Results 51 to 60 of about 25,234 (166)

SGLT2 Inhibitors in Liver Patients [PDF]

Clinical Gastroenterology and Hepatology, 2020
John Chen Hsiang, Vincent Wai-Sun Wong
openaire   +2 more sources

SGLT2 Inhibitors in ADPKD

Journal of the American Society of Nephrology
Abstract Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a leading cause of kidney failure worldwide. Disease progression is driven by cyst expansion, tubular injury, and maladaptive metabolic and hemodynamic changes.
Marie Therese Bou Antoun, Abdul Hamid Borghol, Levon Souvalian, Mohamad Hadla, Georges Abboud, Ahmad Ghanem, Fadi George Munairdjy Debeh, Jean Marc Mardirossian, Mahdi Salih, Pranav S. Garimella, Volker Vallon, Fouad T. Chebib   +11 more
openaire   +1 more source

SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEARTResearch in context

The Lancet Regional Health. Europe
Summary: Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce rates of heart failure hospitalisations and cardiovascular death in patients with type 2 diabetes and prior cardiovascular disease.
Hans Christian Rosén, Moman A. Mohammad, Tomas Jernberg, Stefan James, Jonas Oldgren, David Erlinge   +5 more
doaj   +1 more source

SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients

Virology Journal
Background Long COVID presents significant health challenges, especially for patients with type 2 diabetes. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors may provide protective effects against COVID-19 complications ...
Han-Wei Yeh, Chung-Hsien Chaou, Shun-Fa Yang, Yu-Hsun Wang, Yu-Hsiang Kuan, Chao-Bin Yeh   +5 more
doaj   +1 more source

Association Between SGLT2 Inhibitor Therapy and the Incidence of Tinnitus in Patients with Type 2 Diabetes: A Retrospective Cohort Study

Audiology Research
Background: Numerous studies have demonstrated the beneficial effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on cardiovascular and renal outcomes in patients with heart failure and chronic kidney disease.
David Ulrich Seidel, Simon Bode, Karel Kostev   +2 more
doaj   +1 more source

Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

Diabetology & Metabolic Syndrome
Background Cancer patients with diabetes are at increased risk for cardiovascular diseases due to common risk factors and well-documented drug-associated cardiotoxicity. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown cardiovascular benefits
Hsiao-Huai Kuo, Kuang-Te Wang, Hsin-Hao Chen, Zih-Yin Lai, Po-Lin Lin, Yung-Jen Chuang, Lawrence Yu-Min Liu   +6 more
doaj   +1 more source

The protective effect of sodium-glucose cotransporter 2 inhibitors and the incidence of ovarian cancer: a nationwide cohort preliminary study

Archives of Medical Science
Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are commonly used antihyperglycemic medications that also exhibit anti-inflammatory and antioxidant effects.
Ke-Hsin Ting, Jing-Yang Huang, Pei-Lun Liao, Chia-Yi Lee, Shun-Fa Yang   +4 more
doaj   +1 more source

Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction

ESC Heart Failure
Aims To explore the potential interaction between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Standard Care in ...
Kieran F. Docherty, John J.V. McMurray, Paul R. Kalra, John G.F. Cleland, Ninian N. Lang, Mark C. Petrie, Michele Robertson, Ian Ford   +7 more
doaj   +1 more source

Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional studyResearch in context

EClinicalMedicine
Summary: Background: The cardiovascular and kidney benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors in people with chronic kidney disease (CKD) are well established.
Anna K. Forbes, William Hinton, Michael D. Feher, William Elson, Mark Joy, José M. Ordóñez-Mena, Xuejuan Fan, Nicholas I. Cole, Debasish Banerjee, Rebecca J. Suckling, Simon de Lusignan, Pauline A. Swift   +11 more
doaj   +1 more source

An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients

Therapeutics and Clinical Risk Management, 2016
Yaowen Wang,1 Xueting Hu,2 Xueying Liu,3 Zengqi Wang2 1Department of Clinical Laboratory, Weifang People’s Hospital, 2Department of Clinical Laboratory, Weifang Traditional Chinese Hospital, Weifang, 3Department of Clinical Laboratory, The Third ...
Wang Y, Hu X, Liu X, Wang Z
doaj